Acetylcysteine
Acetylcysteine - Related Videos
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
0 Views •
Cited by 18 •
2017
Current treatments of inflammatory bowel diseases (IBD) aim at alleviating disease symptoms but may cause severe side effects. Thus, alternative strategies are being investigated in animal colitis models. Here, we explain how the beneficial effects of diet supplements on clinical IBD signs are analyzed in such a colitis model.
02:44
In Vitro Gut Model to Assess Bacterial Adhesion and Internalization
0 Views •
2026
Source: Calatayud Arroyo, M., et al. Assessing the Viability of a Synthetic Bacterial Consortium on the In Vitro Gut Host-microbe Interface. J. Vis. Exp. (2018).This video demonstrates an in vitro gut host–microbe model to study bacterial viability. A co-culture of Caco-2 and HT29-MTX cells is incubated with bacteria pre-treated under simulated digestive conditions. Epithelial barrier integrity is assessed using transepithelial electrical resistance, and fractions from the medium, solubilized...
03:28
Fluorescent Probe Imaging Assay: A Technique to Visualize Oxidative Stress in the Reactive Oxygen Species Inducer-Treated Cultured Intestinal Organoid Cells
0 Views •
2025
This video describes the technique of visualizing oxidative stress in cultured organoids. This work helps in understanding the level of oxidative stress due to ROS accumulation in the various cell types present in an organoid after treatment with different ROS modulators.
12:03
Viability Assays for Cells in Culture
0 Views •
Cited by 39 •
2014
Therapeutic compounds are often first examined in vitro with viability assays. Blind cell counts by a human observer can be highly sensitive to small changes in cell number but do not assess function. Computerized viability assays, as described here, can assess both structure and function in an objective manner.
11:36
Glycan Node Analysis: A Bottom-up Approach to Glycomics
0 Views •
Cited by 16 •
2016
This article presents an enhanced form of a novel bottom-up glycomics technique designed to analyze the pooled compositional profile of glycans in unfractionated biofluids through the chemical breakdown of glycans into their constituent linkage-specific monosaccharides for detection by GC-MS. Potential applications include early detection of cancer and other glycan-affective disorders.
FAQs
Its sulfhydryl group chemically disrupts disulfide bonds within mucin, the protein-rich component that contributes to mucus structure. Breaking these bonds reduces the viscosity of secretions rather than relying on a metabolic antioxidant effect. This distinction explains why the drug can modify mucus directly when used for respiratory conditions.
Acetylcysteine supplies cysteine, which supports synthesis of glutathione, an antioxidant involved in detoxification. In acetaminophen overdose, glutathione helps address the reactive metabolite NAPQI. The drug’s value in this setting therefore comes from supporting a metabolic defense pathway, not from its ability to alter mucus structure.
Treatment effectiveness is influenced by how much acetylcysteine is given, when therapy begins, and how the drug is administered. These variables affect whether the intended mucolytic or protective action is achieved effectively. Pharmacological evaluation must therefore consider the treatment conditions, rather than viewing the compound’s presence alone as sufficient.
One action is a direct chemical effect on mucin, where sulfhydryl groups disrupt disulfide bonds and reduce mucus viscosity. The other is an indirect metabolic effect that supports glutathione synthesis and detoxification of NAPQI. Recognizing these distinct mechanisms helps connect the same compound to two different therapeutic purposes.
The intended use depends on the clinical problem. For respiratory conditions, acetylcysteine is administered to modify mucus by lowering its viscosity. Following acetaminophen overdose, it is used to support glutathione-dependent protection against NAPQI. These applications require different pharmacological goals even though they involve the same agent.
Acetylcysteine demonstrates that a single compound can produce clinically useful effects through both chemical and metabolic mechanisms. Its action on mucin represents direct modification of a biological material, whereas its role in acetaminophen toxicity involves precursor support for a protective pathway. This makes it a useful example of mechanism-dependent therapeutic application.